AAP News Vol. 13 No. 2 February 1997, p. 3
© 1997 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zanzola, L.
Right arrow Search for Related Content

 Previous Article  |  Next Article 

ADHD update

Luann Zanzola

Correcting widespread media claims of a six-fold expansion in methylphenidate (Ritalin) treatment for attention deficit disorder (ADD), time trend findings from national and regional data sources showed only a 2.5-fold increase in such treatment between 1990 and 1995 among youths with ADD.

In mid-1995, 1.5 million (2.8 percent) Americans ages 5 to 18 were receiving the medication. Among reasons for the trend, researchers cited: more ADD patients continuing medication into their teens; increased use of medication for girls with ADD and for non-hyperactive ADD students; and increasingly positive public perceptions regarding medication of youths with ADD.